Medical Act amendments a milestone for specialist training, says MMA
KUALA LUMPUR: The Malaysian Medical Association (MMA) has expressed its support for the government's amendments to the Medical Act, which are set to take effect on July 1, describing them as both timely and decisive.
The amendments aim to address issues related to the Parallel Pathway programmes and to streamline the recognition of specialist qualifications and training.
MMA president Datuk Dr Kalwinder Singh Khaira said the amendments mark a significant milestone that will bring greater structure, transparency and legal clarity to the implementation of both the Parallel Pathway and local Master's programmes.
"We wish to record our appreciation to the Health Minister and the Health Ministry for their firm commitment to strengthening the framework for specialist medical training in the country.
"We also thank the MOH's Medical Development Division for their tireless efforts in making this initiative a reality.
"The work that has gone into realising these regulatory changes is a testament to their professionalism and dedication," he said in a statement today.
Health Minister Datuk Seri Dr Dzulkefly Ahmad previously confirmed that the amendment has been signed and will be resubmitted to the Attorney-General's Chambers (A-GC) for the gazettement process.
Dr Kalwinder said the move reflects the urgent need to expand access to high-quality specialist training to meet the increasing demands of the healthcare system, while upholding patient safety and maintaining the highest standards of medical practice.
"The MMA looks forward to continued engagement with the ministry and all relevant stakeholders to ensure that the implementation of these amendments is smooth, fair and in the best interests of both the healthcare system and the public."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Star
3 hours ago
- The Star
Basic health insurance scheme still in the works
PETALING JAYA: The government's proposed basic health insurance scheme, aimed at cushioning Malaysians from rising medical costs, is still in the early stages of development. It is understood that the scheme will be operated by private insurance companies and primarily target the M40 and T20 income groups that rely on private healthcare. Finance Minister II Datuk Seri Amir Hamzah Azizan recently said the government is exploring the possibility of introducing a basic medical insurance plan to ease the public's financial burden in the face of escalating healthcare expenses. Federation of Malaysian Consumers Associations secretary-general Dr Saravanan Thambirajah described the proposal as a progressive step, provided that it is designed to improve access and affordability for all Malaysians. 'To genuinely serve the people, this scheme must not become just another commercial product that enriches private insurers or healthcare providers at the expense of consumers,' he said. Saravanan stressed that the insurance plan must be treated as a public good, designed, managed, and enforced by the government with a strong emphasis on equity, transparency and affordability. He also criticised the current state of private healthcare and insurance in Malaysia, saying both sectors operate with minimal oversight. 'Medical inflation continues to rise sharply because private hospitals are free to set their own fees with little scrutiny. 'Meanwhile, private insurance premiums increase disproportionately with age, often pricing out the elderly and those with pre-existing conditions,' he said. To address this, Saravanan urged the Health Ministry to establish an independent and powerful regulatory body to oversee the private healthcare sector. Such an agency, he said, must have the authority to set service price ceilings, standardise treatment costs, ensure fair billing, and mandate hospitals to publish their fees and provide clear cost estimates upfront. Health economist Prof Dr Maznah Dahlui of Universiti Malaya said if the scheme is designed as a social or national health insurance programme, it could play a crucial role in sustaining the country's healthcare system amid rising disease burdens and costs. 'But if it turns out to be just another form of private health insurance, we risk going down the path of the United States,' she said. Dr Maznah called on the government to come up with a national health fund to ensure universal basic coverage, with the option for those who can afford it to top up with private insurance or out-of-pocket payments. As for the B40 group, she said they can be subsidised by the government, if their medical expenses exceed the scheme's coverage limit. Dr Maznah also expressed concern over the decision to allow Employees Provident Fund savings to be used for private health insurance premiums instead of for social health insurance. She said private insurance should only be paid for out-of-pocket or funded by employers. Prof Dr Sharifa Ezat Wan Puteh, a health economics and public health specialist from Universiti Kebangsaan Malaysia, said the government's idea is well intentioned but needs careful structuring. 'The issue is which bracket will be paying premiums, from which fund, and which income bracket will be subsidised through public fund?' she said. Dr Sharifa stressed that the basic medical insurance should cover essential services, basic procedures, and access to secondary and tertiary care, with some co-payments. She said if premiums are set too low, it could jeopardise the quality of care, with the low-income group affected the most.
The Star
a day ago
- The Star
Medical specialist training gets legal clarity on July 1
PETALING JAYA: There will be greater structure, transparency and legal clarity of both streams of specialist training – the Parallel Pathway and local Master's programmes – once the amendments to the Medical Act come into effect next month, says the Malaysian Medical Association (MMA). Its president Datuk Dr Kalwinder Singh Khaira expressed his appreciation for the Health Ministry's commitment in strengthening the specialist medical training framework. 'We commend the ministry's clear and timely action in fulfilling its promise to implement the amended Medical Act without undue delay,' he said in a statement yesterday. The association also thanked the ministry's Medical Development Division in making the initiative possible. 'The work that has gone into realising these regulatory changes is testament to their professionalism and dedication. 'It also reflects the urgent need to expand access to high-quality specialist training in order to meet the growing demands of our healthcare system, while maintaining patient safety and the highest standards in medical practice,' Dr Kalwinder added. MMA, he said, looks forward to continued engagement with the ministry and all relevant stakeholders to ensure the implementation of these amendments will be smooth, fair and in the best interest of the people. Dr RA Lingeshwaran lauded the Health Ministry's move, saying that many participants of the parallel pathway programme were appreciative of the effort. 'I believe they are all very positive that the amendments finally addressed their concerns,' said the senator, who is a former Sungai Bakap hospital director. Independent health advocate Dr Sean Thum said most feedback from trainees and junior doctors was not solely about the amendments to the Medical Act, but about the structural bottleneck that persists before doctors can even enter specialist training programmes. 'Previously, any eligible doctor could enrol in the parallel pathway programme such as those offered by Royal Colleges abroad. 'The new framework rightly aims to standardise training quality, ensure adequate case exposure and improve supervisor-trainee ratios. 'From a public health perspective, this is a positive move towards safeguarding patient care standards,' he said. The amendments to the Medical Act, which aim to resolve the issue of parallel pathway programmes and streamline the recognition of qualifications and specialised training, will come into effect on July 1. In announcing this, Health Minister Datuk Seri Dr Dzulkefly Ahmad said he had signed the order to enforce the amendments to the Act, which will be resubmitted to the Attorney General's Chambers for gazettement.
The Star
2 days ago
- The Star
Cambodia launches long-acting injectable HIV prevention drug Cabotegravir
PHNOM PENH (Xinhua): Cambodia has launched a long-acting injectable HIV prevention drug, Cabotegravir for Pre-Exposure Prophylaxis (CAB-PrEP), targeting individuals at high risk of HIV infection. Speaking at the launching event in Phnom Penh, Health Ministry's Secretary of State Youk Sambath said CAB-PrEP is required to be injected every two months and it is up to 95 per cent efficacious in preventing HIV infection. HIV is the virus that causes AIDS. "CAB-PrEP is a new option for high-risk groups to prevent themselves from infecting HIV more effectively," she said. "Cambodia is the first country in the region to implement the long-acting injectable Cabotegravir as HIV Pre-Exposure Prophylaxis," she added. Sambath said in the first phase, CAB-PrEP is available at the National Clinic for AIDS, Dermatology and Sexually Transmitted Diseases, the Tuol Kork Health Centre, and the Chhouk Sar Association in Phnom Penh. She said CAB-PrEP provides a new choice, alongside oral PrEP, which has been introduced in the Southeast Asian country since 2019. Sambath said Cambodia is committed to achieving the 95-95-95 HIV treatment targets by the end of 2025. The targets mean 95 per cent of the people who are living with HIV know their HIV status, 95 per cent of the people who know that they are living with HIV are on lifesaving antiretroviral treatment, and 95 per cent of people who are on treatment are virally suppressed. According to the National Centre for HIV/AIDS, Dermatology and Sexually Transmitted Diseases, Cambodia has roughly 76,000 people living with HIV/AIDS, of which 69,413 have received antiretroviral drugs. Some 7,000 people were still unaware that they were infected with HIV, and had not yet received antiretroviral drugs, the NCHADS said. - Bernama-Xinhua
